

Lumigan - (0.01%; Solution/Drops, Opthalmic)

Generic Name	Bimatoprost	Innovator	Allergan
Dosage	0.01%; Solution/Drops, Opthalmic	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	LUMIGAN 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.



Lumigan - (0.03% Solution/ Drops; Ophthalmic)

Generic Name	Bimatoprost	Innovator	Allergan
Dosage	0.03% Solution/ Drops; Ophthalmic	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	More Than 5
Indication	Lumigan (bimatoprost) lowers pressure in the eye by increasing the amount of fluid that drains from the eye. Lumigan eye drops are used to treat certain types of glaucoma and other causes of high pressure inside the eye		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.